A protein in the brain that could play a key role in regulating the creation of a major component that contributes to the development of Alzheimer's disease has been discovered by scientists.
Researchers at Temple University's School of Medicine, led by Domenico Pratico, discovered the presence of the protein, called 12/15-Lipoxygenase, in the brain three years ago.
Brain Exercises to Improve Memory
An active brain can certainly help in improving memory by strengthening the connections between neural impulses in brain.
Advertisement
"We found this protein to be very active in the brains of people who have Alzheimer's disease," Pratico said.
"But three years ago, we didn't know the role it played in the development of the disease," he said.
Following two years of study, the researchers found that the protein is at the top of a pathway and controls a biochemical chain reaction that begins the development of Alzheimer's.
![Head Injury]( "Head Injury")
Head injury or traumatic brain injury is a leading cause of disability among children and young adults that leads to varying degrees of physical and mental stability. Fortunately, it is also one of the preventable brain disorder.
Pratico said that their research has shown that 12/15-Lipoxygenase controls Beta secretase (BACE-1), an enzyme that is key to the development of amyloid plaques in Alzheimer's patients.
"For reasons we don't yet know, in some people, 12/15-Lipoxygenase starts to work too much.
"By working too much, it sends the wrong message to the Beta secretase, which in turn starts to produce more amyloid beta. This initially results in cognitive impairment, memory impairment and, later, an increase of amyloid plaque," Pratico said.
Pratico said that BACE-1 has long been a biological target for researchers seeking to create a drug against Alzheimer's disease. But because little has been known about how it functions, they have been unsuccessful developing a molecule that could reach the brain and block it.
"We now know much better how Beta secretase works because we have found that the 12/15-Lipoxygenase protein is a controller of BACE functions.
"You don't need to target the Beta secretase directly because the 12/15-Lipoxygenase is really the system in the brain that tells BACE to work more or work less," Pratico said.
Pratico said that they have validated 12/15-Lipoxygenase as a target for a potential Alzheimer drug or therapy.
"By modulating BACE levels and activity through controlling the 12/15-Lipoxygenase, we can potentially improve the cognitive part of the phenotype of the disease, and prevent the accumulation of amyloid beta inside the neurons, which will eventually translate into less of those plaques," he said. "This is a totally new mechanism for controlling BACE," Pratico added.
Pratico said his group has looked at an experimental compound that blocks 12/15-Lipoxygenase function as a potential therapy to inhibit BACE function in the brain. In their lab, using animal models, they saw the drug's ability to restore some cognitive function, as well as improve learning and memory ability.
The study has been published in the journal Annals of Neurology.
Source: ANI
Following two years of study, the researchers found that the protein is at the top of a pathway and controls a biochemical chain reaction that begins the development of Alzheimer's.
Head Injury
Head injury or traumatic brain injury is a leading cause of disability among children and young adults that leads to varying degrees of physical and mental stability. Fortunately, it is also one of the preventable brain disorder.
Advertisement
Pratico said that their research has shown that 12/15-Lipoxygenase controls Beta secretase (BACE-1), an enzyme that is key to the development of amyloid plaques in Alzheimer's patients.
"For reasons we don't yet know, in some people, 12/15-Lipoxygenase starts to work too much.
"By working too much, it sends the wrong message to the Beta secretase, which in turn starts to produce more amyloid beta. This initially results in cognitive impairment, memory impairment and, later, an increase of amyloid plaque," Pratico said.
Pratico said that BACE-1 has long been a biological target for researchers seeking to create a drug against Alzheimer's disease. But because little has been known about how it functions, they have been unsuccessful developing a molecule that could reach the brain and block it.
"We now know much better how Beta secretase works because we have found that the 12/15-Lipoxygenase protein is a controller of BACE functions.
"You don't need to target the Beta secretase directly because the 12/15-Lipoxygenase is really the system in the brain that tells BACE to work more or work less," Pratico said.
Pratico said that they have validated 12/15-Lipoxygenase as a target for a potential Alzheimer drug or therapy.
"By modulating BACE levels and activity through controlling the 12/15-Lipoxygenase, we can potentially improve the cognitive part of the phenotype of the disease, and prevent the accumulation of amyloid beta inside the neurons, which will eventually translate into less of those plaques," he said. "This is a totally new mechanism for controlling BACE," Pratico added.
Pratico said his group has looked at an experimental compound that blocks 12/15-Lipoxygenase function as a potential therapy to inhibit BACE function in the brain. In their lab, using animal models, they saw the drug's ability to restore some cognitive function, as well as improve learning and memory ability.
The study has been published in the journal Annals of Neurology.
Source: ANI
Brain Tumor
Brain tumors are the abnormal growth of brain cells that may be benign or metastatic. Brain tumors account for about 2.4% of all the tumor diagnosesandare most challenging due to their critically delicate location.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Research News
Cerebrospinal fluid (CSF) leaks are detected in approximately 1-3% of adults who have experienced a traumatic brain injury.
The optogenetic activation of hippocampal astrocytes can be viewed as a novel therapeutic avenue for addressing Alzheimer's disease.
In Alzheimer's disease condition, the control and adjustment of ABCA7 levels in response to inflammation and the decrease in the availability of cholesterol.
Atopic dermatitis (AD) and inflammatory bowel disease (IBD) can lead to alterations in the microbiome, and disruptions in the skin and gut barrier.
Gaining insights into mortality risks among vitiligo patients will enhance patient counseling, healthcare monitoring, and overall patient management strategies.
